Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Non-Current Deffered Revenue: 2015-2017

Historic Non-Current Deffered Revenue for Aytu Biopharma (AYTU) over the last 2 years, with Jun 2017 value amounting to $1,451.

  • Aytu Biopharma's Non-Current Deffered Revenue fell 82.34% to $1,451 in Q2 2017 from the same period last year, while for Jun 2017 it was $1,451, marking a year-over-year decrease of 82.34%. This contributed to the annual value of $1,451 for FY2017, which is 82.34% down from last year.
  • Aytu Biopharma's Non-Current Deffered Revenue amounted to $1,451 in Q2 2017, which was down 53.48% from $3,119 recorded in Q1 2017.
  • Over the past 5 years, Aytu Biopharma's Non-Current Deffered Revenue peaked at $425,893 during Q2 2015, and registered a low of $1,451 during Q2 2017.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $8,215 (2016), whereas its average is $177,670.
  • Data for Aytu Biopharma's Non-Current Deffered Revenue shows a maximum YoY plummeted of 99.14% (in 2017) over the last 5 years.
  • Over the past 3 years, Aytu Biopharma's Non-Current Deffered Revenue (Quarterly) stood at $383,036 in 2015, then tumbled by 98.75% to $4,787 in 2016, then slumped by 82.34% to $1,451 in 2017.
  • Its last three reported values are $1,451 in Q2 2017, $3,119 for Q1 2017, and $4,787 during Q4 2016.